Application of PI3K inhibitor in preparation of drug for treating drug resistance to FLT3 inhibitor

Abstract

The invention provides an application of a PI3K inhibitor in preparation of a drug for treating drug resistance to an FLT3 inhibitor, and the PI3K inhibitor can inhibit an excessively activated PI3K-Akt pathway so as to generate a stronger killing effect on acute myelogenous leukemia cells which are resistant to the FLT3 inhibitor.

Description

technical field [0001] The invention belongs to the field of acute myeloid leukemia drugs, and in particular relates to the application of PI3K inhibitors in the preparation of drugs for treating resistance to FLT3 inhibitors. Background technique [0002] Acute myeloid leukemia (AML) is a malignant clonal disease of the hematopoietic system caused by the continuous proliferation of myeloid hematopoietic stem / progenitor cells, and is the most common hematological malignancy in adults. The rate is low, and without active treatment, the survival period of most patients is only a few weeks to a few months. [0003] FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that is highly expressed in hematopoietic stem cells. It undergoes dimerization and phosphorylation through ligand binding, thereby activating downstream Signaling pathway to regulate the differentiation and maturation of hematopoietic progenitor cells. Tandem repeats (internal duplications, I...

AI Technical Summary

Problems solved by technology

Although FLT3 kinase inhibitors have shown significant therapeutic effects and clinical application prospects, the emergence of drug resistance is still a major problem that cannot be ignored. Effective treatment means, once drug resistance occurs, the patient's disease progresses rapidly and there is no more effective treatment drug, therefore, it is very important to develop a drug treatment plan for drug-resistant patients

Images